Drug Approval | January 19, 2024
Zydus and Synthon inks licensing and supply agreement for Palbociclib Tablets for US market
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Febuxostat Tablets (RLD Uloric) had estimated annual sales of US$ 27 million in the U.S. (IQVIA MAT November 2023)
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
The PAI was conducted for two drug product applications (ANDAs) filed from this facility
The launch will enable PCC to further expand their existing Zinc Sulfate Injection product line and overall the generic injectables portfolio
Collaboration streamlines patient access to oncology clinical trials
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
Inducts advanced AI-Powered 24x7 remote patient monitoring system
Subscribe To Our Newsletter & Stay Updated
